What are the opening hours?

Monday 6am - 4pm Tuesday 6am - 4pm Wednesday 6am - 4pm Thursday 6am - 4pm Friday 6am - 4pm

Oasis Diagnostics Corporation

Home
United States
Portland, OR
Oasis Diagnostics Corporation

Non-invasive saliva based technology for rapid testing, sample collection & molecular diagnostics

Oasis Diagnostics® Corporation was founded to address a growing need for non-invasive saliva based technology for rapid testing, sample collection, and molecular diagnostics.

04/03/2026

Saliva liquid biopsy does not have to be complicated.

At Oasis Diagnostics, we believe the front end of discovery matters just as much as the downstream analysis. When researchers want to isolate high value targets such as exosomes, cell free DNA, cell free RNA, and proteins from saliva, the collection method needs to be simple, standardized, and practical.

That is exactly where our Pure•SAL™ and RNAPro•SAL™ devices fit in.

Pure•SAL™ and RNAPro•SAL™ are two rapid non-invasive liquid biopsy platforms that support standardized collection workflows for cell free fractions [DNA, RNA], miRNA, and proteins. These devices remove interfering factors during the very short [3 Minute] collection process thereby simplifying sample collection to support the future growth of saliva in molecular and proteomic workflows.

One sample. Multiple analytes. Less collection friction.

For teams working across PCR, qPCR/dPCR, NGS, sequencing, proteomics, ELISA, and lateral flow applications, saliva offers a compelling path forward when the collection process is done right.

That is the opportunity.

04/02/2026

Let’s play a quick game. 👇

Guess the specimen:

✔ Non-invasive
✔ Easy to collect
✔ Useful across a growing range of research and diagnostic applications
✔ Often underestimated

What is it?

You already know the answer. 😄
It’s saliva — and at Oasis, we think it deserves way more attention for the role it can play in expanding access, simplifying collection, and supporting the future of diagnostics.

Sometimes the most powerful tools are the ones people overlook.

04/01/2026

It was a pleasure to finally meet Gary in person after we had been connected for several months. Gary is with PDS Health, formerly Pacific Dental Services, a major organization in the dental space that supports dentist-owned practices and has built a broad national footprint. It was great to connect, learn more about the work they are doing, and have the opportunity to continue building the relationship face to face.

03/31/2026

Last week, I had the opportunity to attend the IADR/AADOCR meeting in San Diego, and it was an important event for Oasis.

This meeting brings together many of the leading voices in dental, oral, and craniofacial research. For Oasis, it was especially significant because IADR continues to be a strong center of activity for salivary science, with researchers, clinicians, and innovators all helping shape the next generation of diagnostic testing.

What makes this community particularly compelling is that many dentists today are not only practitioners and researchers, but also entrepreneurial leaders. Many are actively involved in the development of new tests for lung and oral cancer, women’s health, liver fibrosis, and many other areas where better, earlier, and more accessible testing can make a real difference.

Several of our important collaborators and development partners were in attendance, so it was valuable to spend time together in person. It was also a great opportunity to connect with members of the Salivary Research Group and meet with researchers working on next-generation saliva-based tests, including some who are already Oasis customers.

Meetings like this are a strong reminder that Oasis is part of a much bigger movement. As saliva continues to gain recognition as a practical and powerful diagnostic specimen, it is exciting to see the science advancing and the community around it growing stronger.

03/30/2026

Last week, I attended the IADR, the International Association for Dental Research, which this year was held as a joint meeting with the American Association for Dental, Oral, and Craniofacial Research (AADOCR) in San Diego. The 2026 IADR/AADOCR/CADR General Session & Exhibition took place March 25–28, 2026, at the San Diego Convention Center and brought together a large international community of researchers, clinicians, and industry leaders.

I had the opportunity to meet and spend time with several important people in our business, including Chamindie Punyadeera, Walter Siqueira, Debora Heller, Hend Alqaderi, David Wong, Sarah Knox, Stefan Ruhl and Dr. Tina Saw. We had a number of very good business discussions throughout the meeting, and each of these conversations was valuable to our work and future direction.

The conference was very well attended and featured many lectures, workshops, and meetings covering the latest developments in dental research, including sessions focused on salivary diagnostics, which is directly aligned with our field. I was also an active participant in IADR’s Salivary Research Group with some of the world’s leading saliva researchers. It was an excellent opportunity to connect with key people, stay current with research updates, and strengthen relationships within the salivary diagnostics community

03/26/2026

Oral-systemic health is not a future concept. It is already reshaping how we think about disease.

A recent preclinical study highlighted by Oral Health Group points to Fusobacterium nucleatum—an oral bacterium associated with periodontal disease—as a possible contributor to accelerated breast cancer growth and spread.

At Oasis Diagnostics, this is exactly why we believe the oral cavity deserves far more attention in modern healthcare.

When oral biology can influence systemic disease, the need for reliable, noninvasive sampling and smarter diagnostic infrastructure becomes even more important. Better insights begin with better specimens, better collection, and better tools for understanding what the mouth may reveal about whole-body health.

The science is still evolving, and this study is preclinical. But the direction is clear: oral health is deeply connected to broader health outcomes.

Read more here: https://www.oralhealthgroup.com/clinical/dental-research/oral-bacterium-tied-to-accelerated-breast-cancer-growth-and-spread-in-preclinical-study-1003994374/

03/25/2026

A timely article from RDH Magazine highlights something dentistry can no longer afford to overlook: dry mouth is not just a minor complaint—it can be an early signal of broader oral and systemic imbalance.

Saliva plays a critical role in protecting the oral environment. It supports buffering, remineralization, microbial balance, immune defense, and tissue health. So when salivary flow declines, the consequences can go far beyond discomfort alone.

At Oasis Diagnostics, this is why we continue to believe saliva deserves a much bigger place in the future of care. From oral hydration awareness to non-invasive saliva-based collection and testing, the opportunity is clear: better attention to saliva can support earlier insight, more personalized care, and stronger connections between oral health and whole-body health.

Dentistry’s next frontier is not only about treating disease once damage appears. It is about recognizing biological changes earlier—and saliva is central to that conversation.

The future of prevention may already be right in front of us.

Source inspiration:https://www.rdhmag.com/patient-care/article/55353721/dry-mouth-is-everywhere-so-why-arent-we-talking-about-it-saliva-systemic-health-and-dentistrys-next-frontier?utm_source=DIQ+Clinical+Insights&utm_medium=email&utm_campaign=CPS260310018&o_eid=9219H4608590G9D&rdx.ident[pull]=omeda|9219H4608590G9D&oly_enc_id=9219H4608590G9D

03/23/2026

Excited to be attending the 2026 IADR/AADOCR/CADR General Session & Exhibition in San Diego, California, from March 25–28, 2026. Looking forward to connecting with the global oral, dental, and craniofacial research community and meeting with valued collaborators David T. Wong, Chamindie Punyadeera, Debora Heller, and Walter Siqueira.

Grateful for the opportunity to be part of conversations that continue to advance innovation, research, and collaboration in this space. Looking forward to the insights, connections, and opportunities this meeting will bring.

Learn more about the event here: https://www.iadr.org/2026iags

03/20/2026

A major step forward for saliva-based diagnostics.

Traditionally, tuberculosis diagnosis relies upon the collection of sputum or blood specimens but new findings from the Yale School of Public Health highlight the strong potential of saliva testing for detecting tuberculosis, with reported high sensitivity and specificity in confirmed cases. This kind of progress reinforces what many in the field have long believed: saliva can play a powerful role in expanding access to faster, simpler, and more patient-friendly diagnostics.

At Oasis Diagnostics, this aligns closely with our mission to advance innovative saliva collection technologies that support broader diagnostic applications across healthcare and research.

As mentioned above traditional TB testing often depends predominantly on sputum samples, which can be difficult for many individuals to provide. Saliva offers a more accessible, non-invasive alternative — one that may help improve testing reach, especially in community settings and among populations where standard sample collection is more challenging.

As more research continues to validate saliva as a reliable diagnostic sample, the opportunity to transform disease detection becomes even clearer.

The future of diagnostics is not only about accuracy — it is also about accessibility, ease, and real-world impact.

Read more here:
https://ysph.yale.edu/news-article/saliva-test-shows-high-accuracy-for-detecting-tuberculosis/

03/19/2026

I’m pleased to share that my conversation on the WellBeing4Me Podcast is now live on Spotify. In this episode, “Dr. Paul D. Slowey on Saliva Diagnostics, HIV Testing & Non-Invasive Health Innovation | Ep. 8,” I discuss the growing role of saliva-based diagnostics, the importance of non-invasive testing, and how innovation can help make healthcare more accessible and patient-friendly.

Saliva has enormous potential to transform the way we think about screening, diagnostics, and monitoring—especially when the goal is to reduce discomfort, expand access, and support earlier detection. I’m grateful for the opportunity to share this conversation and the broader vision behind this work.

Give it a listen on Spotify and let me know your thoughts.

🎧 Listen here: https://open.spotify.com/episode/2jNS0sDurregkF4O0U7wFq?si=g6oAhn2eTdC9Jkhkcukd8A

03/18/2026

The Alzheimer’s Association has opened three Part the Cloud Translational (PTC) Research Grant opportunities for Alzheimer’s disease and related dementias (AD/ADRD).

These funding opportunities are designed to help advance promising translational research across several important areas:

🔹 Combination Therapies Program (PTC-CTP)
Supports biomarker-informed combination clinical trials, including drug-drug, drug-behavioral, drug-device, and other combination approaches.

🔹 Enable the Molecule for AI-Discovered Programs (PTC-EM-AI)
A new initiative focused on advancing AI/ML-discovered therapeutic programs through lead optimization and IND-enabling stages.

🔹 Phase 1 and Phase 2 Clinical Studies
Supports early-stage human clinical trials evaluating novel or repurposed therapies for Alzheimer’s disease and related dementias.

Key Dates:
📌 Letter of Intent due: March 26, 2026 – 5:00 p.m. ET
📌 Full application due: April 30, 2026 – 5:00 p.m. ET
📌 Award notifications: By July 15, 2026

This is an important opportunity for academic investigators, small companies, and translational researchers working to move innovation forward in AD/ADRD research.

For full details, visit alz.org/grants.

03/17/2026

I am deeply honored to share that I continue to serve as a co-chair of the ISTAART Biofluid Based Biomarkers (BBB) Professional Interest Area Work Group on Saliva Biomarkers for Dementia Research, but more importantly I wanted to share the message that our Working Group are now inviting interested new members to join our growing membership as we advance the use of saliva for Alzheimer’s disease and related dementias (AD/ADRD) testing, diagnosis, and monitoring.

Saliva has tremendous potential as a scalable, low-cost, and minimally invasive biofluid, especially for large-scale screening, longitudinal studies, and broader use in primary care and low-resource settings.

Building on our recent publication on optimal saliva collection and pre-analytic handling, this working group will focus on standardization, validation across cohorts, and strengthening the role of saliva as a credible complementary biofluid in AD/ADRD research.

I’m grateful to co-chair this effort alongside Dr. Chi Udeh-Momoh and Dr. Henrik Zetterberg.

Our launch meeting will be held on Thursday, May 7, 2026, at 1:05 p.m. CT.

If you are a BBB PIA member with interest in this area, we would be delighted to have you join us. Even if you cannot attend the first call, registering will ensure you receive future updates and invitations.

Register here: https://forms.monday.com/forms/9fd36c63f07fe748a96c1facdf6dd86d?r=use1

Address

5920 NE 112th Avenue
Portland, OR
97220

Opening Hours

Monday	6am - 4pm
Tuesday	6am - 4pm
Wednesday	6am - 4pm
Thursday	6am - 4pm
Friday	6am - 4pm

Telephone

+13605461563

Website

http://www.4saliva.com/

Alerts

Be the first to know and let us send you an email when Oasis Diagnostics Corporation posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Oasis Diagnostics Corporation:

Shortcuts

Address
Telephone
Opening Hours
Alerts
Contact The Practice
Claim ownership or report listing

Want your practice to be the top-listed Clinic in Portland?